331 related articles for article (PubMed ID: 34309913)
21. Repeat measurements of uterine artery pulsatility index, mean arterial pressure and serum placental growth factor at 12, 22 and 32 weeks in prediction of pre-eclampsia.
Andrietti S; Carlucci S; Wright A; Wright D; Nicolaides KH
Ultrasound Obstet Gynecol; 2017 Aug; 50(2):221-227. PubMed ID: 28078815
[TBL] [Abstract][Full Text] [Related]
22. Prospective evaluation of first-trimester screening strategy for preterm pre-eclampsia and its clinical applicability in China.
Hu J; Gao J; Liu J; Meng H; Hao N; Song Y; Ma L; Luo W; Sun J; Gao W; Meng W; Sun Y
Ultrasound Obstet Gynecol; 2021 Oct; 58(4):529-539. PubMed ID: 33817865
[TBL] [Abstract][Full Text] [Related]
23. Biophysical and biochemical markers at 30-34 weeks' gestation in the prediction of adverse perinatal outcome.
Valiño N; Giunta G; Gallo DM; Akolekar R; Nicolaides KH
Ultrasound Obstet Gynecol; 2016 Feb; 47(2):194-202. PubMed ID: 26094952
[TBL] [Abstract][Full Text] [Related]
24. Second-trimester contingent screening for small-for-gestational-age neonate.
Nowacka U; Papastefanou I; Bouariu A; Syngelaki A; Akolekar R; Nicolaides KH
Ultrasound Obstet Gynecol; 2022 Feb; 59(2):177-184. PubMed ID: 34214232
[TBL] [Abstract][Full Text] [Related]
25. Competing risks model in screening for preeclampsia by maternal factors and biomarkers at 19-24 weeks' gestation.
Gallo DM; Wright D; Casanova C; Campanero M; Nicolaides KH
Am J Obstet Gynecol; 2016 May; 214(5):619.e1-619.e17. PubMed ID: 26627730
[TBL] [Abstract][Full Text] [Related]
26. Screening for pre-eclampsia by maternal serum glycosylated fibronectin at 11-13 weeks' gestation.
Sokratous N; Bednorz M; Sarli P; Morillo Montes OE; Syngelaki A; Wright A; Nicolaides KH
Ultrasound Obstet Gynecol; 2023 Oct; 62(4):504-511. PubMed ID: 37401855
[TBL] [Abstract][Full Text] [Related]
27. Prediction of hypertensive disorders after screening at 36 weeks' gestation: comparison of angiogenic markers with competing-risks model.
Schiattarella A; Magee LA; Wright A; Syngelaki A; Akolekar R; Von Dadelszen P; Nicolaides KH
Ultrasound Obstet Gynecol; 2023 Sep; 62(3):345-352. PubMed ID: 37329494
[TBL] [Abstract][Full Text] [Related]
28. Comparison of ophthalmic artery Doppler with PlGF and sFlt-1/PlGF ratio at 35-37 weeks' gestation in prediction of imminent pre-eclampsia.
Lau K; Wright A; Sarno M; Kametas NA; Nicolaides KH
Ultrasound Obstet Gynecol; 2022 May; 59(5):606-612. PubMed ID: 35132725
[TBL] [Abstract][Full Text] [Related]
29. Competing-risks model in screening for pre-eclampsia by maternal factors and biomarkers at 35-37 weeks' gestation.
Andrietti S; Silva M; Wright A; Wright D; Nicolaides KH
Ultrasound Obstet Gynecol; 2016 Jul; 48(1):72-9. PubMed ID: 26566592
[TBL] [Abstract][Full Text] [Related]
30. Comparison of competing-risks model with angiogenic factors in midgestation screening for preterm growth-related neonatal morbidity.
Papastefanou I; Menenez M; Szczepkowska A; Gungil B; Syngelaki A; Nicolaides KH
Ultrasound Obstet Gynecol; 2024 May; 63(5):613-618. PubMed ID: 38057964
[TBL] [Abstract][Full Text] [Related]
31. Development of pre-eclampsia within 4 weeks of sFlt-1/PlGF ratio > 38: comparison of performance at 31-34 vs 35-37 weeks' gestation.
Dragan I; Wright D; Fiolna M; Leipold G; Nicolaides KH
Ultrasound Obstet Gynecol; 2017 Feb; 49(2):209-212. PubMed ID: 27671743
[TBL] [Abstract][Full Text] [Related]
32. Biophysical and biochemical markers at 35-37 weeks' gestation in the prediction of adverse perinatal outcome.
Valiño N; Giunta G; Gallo DM; Akolekar R; Nicolaides KH
Ultrasound Obstet Gynecol; 2016 Feb; 47(2):203-9. PubMed ID: 26224608
[TBL] [Abstract][Full Text] [Related]
33. Biomarkers of impaired placentation at 35-37 weeks' gestation in the prediction of adverse perinatal outcome.
Ciobanou A; Jabak S; De Castro H; Frei L; Akolekar R; Nicolaides KH
Ultrasound Obstet Gynecol; 2019 Jul; 54(1):79-86. PubMed ID: 31100188
[TBL] [Abstract][Full Text] [Related]
34. Ophthalmic artery Doppler and biomarkers of impaired placentation at 36 weeks' gestation in pregnancies with small fetuses.
Arechvo A; Wright A; Nobile Recalde A; Liandro R; Charakida M; Nicolaides KH
Ultrasound Obstet Gynecol; 2024 Mar; 63(3):358-364. PubMed ID: 37902727
[TBL] [Abstract][Full Text] [Related]
35. Comparison of screening for pre-eclampsia at 31-34 weeks' gestation by sFlt-1/PlGF ratio and a method combining maternal factors with sFlt-1 and PlGF.
Tan MY; Wright D; Koutoulas L; Akolekar R; Nicolaides KH
Ultrasound Obstet Gynecol; 2017 Feb; 49(2):201-208. PubMed ID: 27671370
[TBL] [Abstract][Full Text] [Related]
36. Competing risks model in screening for preeclampsia by maternal factors and biomarkers at 30-34 weeks' gestation.
Tsiakkas A; Saiid Y; Wright A; Wright D; Nicolaides KH
Am J Obstet Gynecol; 2016 Jul; 215(1):87.e1-87.e17. PubMed ID: 26875953
[TBL] [Abstract][Full Text] [Related]
37. Pre-eclampsia screening in Denmark (PRESIDE): national validation study.
Riishede I; Rode L; Sperling L; Overgaard M; Ravn JD; Sandager P; Skov H; Wagner SR; Nørgaard P; Clausen TD; Jensen CAJ; Pihl K; Jørgensen FS; Munk JK; Zingenberg HJ; Pedersen NG; Andersen MR; Wright A; Wright D; Tabor A; Ekelund CK
Ultrasound Obstet Gynecol; 2023 Jun; 61(6):682-690. PubMed ID: 36840981
[TBL] [Abstract][Full Text] [Related]
38. The International Federation of Gynecology and Obstetrics (FIGO) initiative on pre-eclampsia: A pragmatic guide for first-trimester screening and prevention.
Poon LC; Shennan A; Hyett JA; Kapur A; Hadar E; Divakar H; McAuliffe F; da Silva Costa F; von Dadelszen P; McIntyre HD; Kihara AB; Di Renzo GC; Romero R; D'Alton M; Berghella V; Nicolaides KH; Hod M
Int J Gynaecol Obstet; 2019 May; 145 Suppl 1(Suppl 1):1-33. PubMed ID: 31111484
[TBL] [Abstract][Full Text] [Related]
39. Longitudinal changes in maternal serum placental growth factor and soluble fms-like tyrosine kinase-1 in women at increased risk of pre-eclampsia.
Khalil A; Maiz N; Garcia-Mandujano R; Penco JM; Nicolaides KH
Ultrasound Obstet Gynecol; 2016 Mar; 47(3):324-31. PubMed ID: 26387758
[TBL] [Abstract][Full Text] [Related]
40. Prediction of small for gestational age neonates: screening by maternal factors, fetal biometry, and biomarkers at 35-37 weeks' gestation.
Ciobanu A; Rouvali A; Syngelaki A; Akolekar R; Nicolaides KH
Am J Obstet Gynecol; 2019 May; 220(5):486.e1-486.e11. PubMed ID: 30707967
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
